Dashboard
Manage Tickers

CRBU Caribou Biosciences, Inc.

Nasdaq cariboubio.com


$ 2.43 $ -0.96 (-28.17 %)    

Monday, 03-Nov-2025 19:59:32 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 2.43
$ 3.39
$ 2.29 x 76
$ 2.44 x 1,000
$ 2.38 - $ 3.54
$ 0.66 - $ 3.54
68,354,934
na
226.29M
$ 2.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-10-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-21-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 09-02-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today
Why Is CRISPR Genome-Editing Firm Caribou ...
11/03/2025 16:48:45

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and mye...

citigroup-maintains-buy-on-caribou-biosciences-raises-price-target-to-8
Citigroup Maintains Buy on Caribou Bioscie...
11/03/2025 15:17:54

Citigroup analyst Yigal Nochomovitz maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price target from ...

caribou-biosciences-shared-its-first-clinical-data-from-dose-escalation-in-the-ongoing-cammouflage-phase-1-trial-of-cb-011-an-off-the-shelf-anti-bcma-car-t-cell-therapy-in-relapsed-or-refractory-multiple-myeloma-the-company-plans-to-share-dose-expansion-data-in-2026
Caribou Biosciences Shared Its First Clini...
11/03/2025 12:14:01

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapse...

caribou-biosciences-released-results-from-its-ongoing-antler-phase-1-trial-of-vispacabtagene-regedleucel-formerly-cb-010-an-allogeneic-anti-cd9-car-t-cell-therapy-for-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma
Caribou Biosciences Released Results From ...
11/03/2025 12:11:09

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous C...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
11/03/2025 12:05:47

why-lucas-gc-shares-are-trading-higher-by-over-36-here-are-20-stocks-moving-premarket
Why Lucas GC Shares Are Trading Higher By ...
11/03/2025 10:09:58

reported-sunday-caribou-biosciences-schedules-webcast-to-share-key-updates-from-antler-and-cammouflage-trials-and-outline-next-steps-for-allogeneic-car-t-pipeline
Reported Sunday, Caribou Biosciences Sched...
11/03/2025 07:53:23

correction-caribou-biosciences-q2-adj-eps-035-beats-039-estimate-sales-2667m-beat-2465m-estimate
CORRECTION: Caribou Biosciences Q2 Adj. EP...
08/12/2025 22:33:13

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $...

fda-halts-trials-exporting-americans-cells-to-hostile-countries-for-genetic-engineering
FDA Halts Trials Exporting Americans' Cell...
06/20/2025 17:59:07

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exempt...

caribou-biosciences-q1-eps-043-beats-044-estimate-sales-235m-beat-175m-estimate
Caribou Biosciences Q1 EPS $(0.43) Beats $...
05/08/2025 20:50:09

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $...

hc-wainwright--co-maintains-buy-on-caribou-biosciences-lowers-price-target-to-3
HC Wainwright & Co. Maintains Buy on Carib...
04/28/2025 17:52:40

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price tar...

caribou-biosciences-discontinues-gallop-phase-1-trial-of-cb-010-for-lupus-reduces-workforce-by-23-estimates-cash-payments-of-25m-35m-from-reduction-in-force-and-prioritization
Caribou Biosciences Discontinues GALLOP Ph...
04/24/2025 20:25:55

caribou-biosciences-prioritizes-oncology-pipeline-streamlines-operations-to-focus-on-cb-010-and-cb-011-clinical-programs-with-clinical-data-disclosures-now-planned-for-h2-2025
Caribou Biosciences Prioritizes Oncology P...
04/24/2025 20:25:05

-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one...

hc-wainwright--co-reiterates-buy-on-caribou-biosciences-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Cari...
03/19/2025 10:59:47

HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price ...

caribou-biosciences-expects-2494m-in-cash-and-equivalents-to-fund-current-operating-plan-into-h2-2026
Caribou Biosciences Expects $249.4M In Cas...
03/10/2025 20:30:28

caribou-biosciences-q4-2024-gaap-eps-039-beats-042-estimate-sales-208m-miss-211m-estimate
Caribou Biosciences Q4 2024 GAAP EPS $(0.3...
03/10/2025 20:12:54

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $...

reported-earlier-caribou-biosciences-advances-cb-010-cb-011-and-cb-012-programs-with-key-clinical-updates-expected-in-2025-cash-position-281m
Reported Earlier, Caribou Biosciences Adva...
01/13/2025 07:33:53

-- CB-010 GALLOP Phase 1 trial initiated in lupus ---- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no D...

b-of-a-securities-maintains-buy-on-caribou-biosciences-lowers-price-target-to-11
B of A Securities Maintains Buy on Caribou...
01/07/2025 17:49:33

B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target ...

caribou-biosciences-appoints-sri-ryali-as-cfo
Caribou Biosciences Appoints Sri Ryali As CFO
01/02/2025 13:08:51

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
11/26/2024 21:06:35

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION